Empagliflozin Versus Vildagliptin in CAD Patients With T2DM
Status:
COMPLETED
Trial end date:
2024-10-10
Target enrollment:
Participant gender:
Summary
We compared the cardioprotective effects of empagliflozin, an SGLT2 inhibitor, with those of vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, focusing on various inflammatory biomarkers lipid profile, and cardiac function, in patients with type 2 diabetes mellitus (T2DM).